DLA Piper advised Iovance Biotherapeutics in the deal. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced its definitive agreement with Clinigen Limited to acquire Proleukin® (aldesleukin), an interleukin-2…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
